Innovations in the Treatment and Management of Chronic Cough: Expert Perspectives on the Role of New and Emerging Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2023, to March 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme LLC

Description:
Chronic cough, which is observed in approximately 12% of the US population, is defined as a cough that lasts for more than 8 weeks. Patients with chronic cough are often distressed by the condition, which can lead to depression, anxiety, a decline in quality of life, and changes to their social activities. The diagnosis and management of chronic cough can be challenging, with only approximately 50% of patients receiving a diagnosis. Recent advances have been made in the understanding and management of refractory chronic cough, with several novel therapies being evaluated in ongoing clinical studies.

 Upon completion of this activity, participants will be able to:

  • Examine current unmet clinical and economic needs of patients with chronic cough and the burden on patient quality of life

  • Explore the underlying causes of chronic cough and strategies to recognize patients with the condition

  • Review the clinical trial data regarding treatment options for refractory chronic cough

  • Explore a treatment plan for patients with chronic cough that takes into consideration the type of cough, comorbidities, cost, and the potential emergence of new therapies

  • Discuss managed care considerations of emerging P2X3 receptor antagonists in the management of chronic cough

     

Faculty: Michael S. Blaiss, MD
Executive Medical Director
American College of Allergy, Asthma, and Immunology
Physician, Good Samaritan Health Clinic of East Gwinnett
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University

Disclosure:

 (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Blaiss has served as a consultant for ALK, Amgen, AstraZeneca, Bellus, Covis, Lanier BioTherapeutics, Merck, Pfizer, and Sanofi/Regeneron. He has served on the speaker's bureau for Merck and Sanofi/Regeneron. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme LLC


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue